LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

STAGO sthemO and sthemE Product Ranges Make World Premiere

By LabMedica International staff writers
Posted on 24 May 2023
Print article
Image: Stago unveiled the sthemO 301 and 201 hemostasis analyzers at EuroMedlab 2023 (Photo courtesy of Stago)
Image: Stago unveiled the sthemO 301 and 201 hemostasis analyzers at EuroMedlab 2023 (Photo courtesy of Stago)

Diagnostica Stago (Asnières-sur-Seine, France) is unveiling its new coagulation line - the sthemO and sthemE product ranges - at WorldLab–EuroMedLab Roma 2023.

Leveraging its proficiency in hemostasis, Stago has diversified its product line to incorporate hematology, becoming a multi-specialist in these fields. The company's new "sthem" brand represents a significant leap towards next-generation Stago solutions. Drawing from over 60 years of partnership with coagulation professionals, Stago has introduced sthemO, a fresh line of hemostasis devices and reagents designed to fulfill the evolving demands of laboratories. The sthemO 301, the first analyzer in the sthemO hemostasis series, is a high-throughput, fully automated coagulation analyzer designed for medium to large laboratories and can be integrated into automated tracks. It offers the perfect combination of expertise, performance, and innovation. Also included in the new range of sthemO analyzers by Stago is the sthemO 201. This bench-top analyzer, suitable for smaller laboratories, offers the same level of efficiency and analytical performance as the sthemO 301. Its simplicity and versatility enable laboratories to concentrate on value-added tasks.

The sthemO analyzers are qualitative and/or quantitative automated hemostasis platforms for in vitro diagnostic use by clinical laboratory staff and are to be used with dedicated sthemO reagents and controls. The company has emphasized technological advancement, integrating an increasing number of features into its sthemO coagulation devices to simplify operations for laboratories and patients alike. The sthemO series incorporates immuno-chemiluminescence technology to provide superior analytical performance and an extensive range of tests. Additionally, Stago has developed a unique cuvette design, compatible with all embedded technologies, to provide a highly efficient, user-friendly system.

In order to optimize these two novel systems, Stago has also launched new eSolutions under the sthemE umbrella. The sthemE Manager is designed to facilitate data and information exchange between one or several in vitro diagnostic analyzers and laboratory information systems. This system, encompassing the sthemE Manager and one or more analyzers, is managed by authorized laboratory personnel. sthemE Manager is not intended for use with specific assays.

Related Links:
Diagnostica Stago

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more